|
Aug 5
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025
|
|
Jul 31
|
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
|
|
Jul 31
|
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
|
|
Jul 29
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025
|
|
Jul 28
|
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
|
|
Jul 24
|
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
|
|
Jul 24
|
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
|
|
Jul 23
|
Ipsen announces changes to its Executive Committee
|
|
Jul 22
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
|
|
Jul 17
|
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
|
|
Jul 16
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025
|
|
Jul 1
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
|
|
Jun 17
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
|
|
Jun 13
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
|
|
Jun 12
|
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Jun 2
|
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
|
|
Jun 2
|
Ipsen S.A. - Initiation of the share buy-back program
|
|
May 31
|
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
|
|
Apr 24
|
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
|
|
Feb 14
|
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
|